Theratechnologies gets soft response to Q1 results

Shares of the Theratechnologies fell in half last June when Ferrer announced it would withdraw the marketing authorization application with the European Medicines Agency for Egrifta, the company's tesamorelin application proposed for the treatment of excess abdominal fat in HIV patients with lipodystrophy.

Shares of Theratechnologies (TSX:TH) are down slightly today after the company reported its Q1, 2015 results. In the quarter, the company lost $914,000 on revenue of $4.56-million, up 72% from Q4’s topline and a significant bump over last year’s Q1 revenue number of $1.67-million. “As first-quarter results demonstrate, Theratechnologies is executing its business plan well,” […]

Patient Home Monitoring increases financing to $58.5-million

Patient Home Monitoring says it intends to benefit from the trends of an aging population and a push by U.S. Medicare to reduce costs by encouraging in-home healthcare services.

High flying healthcare player Patient Home Monitoring (TSXV:PHM) has upped its previously announced financing. The company, which has seen its shares more than quadruple since last fall, says it will now raise $58.5-million in a bought deal led by Mackie Research Capital with a syndicate that is comprised of GMP and Beacon. The company will […]

How Technology Can Protect Consumers and Pharma Companies From Fake Drugs


This report was adapted by Cantech Letter from a piece prepared by Sophic Capital. For the original report, and more in-depth research, please visit Sophic Capital’s website, here. The counterfeit pharmaceutical industry could be worth as much as $200 billion annually, which is slightly less than the $246 billion illicit drug trade. Criminal organizations are […]

Buy BioSyent on weakness, says Cantor Fitzgerald Canada

Biosyent's leading brand is FeraMAX. It currently markets two formulations for the treatment of iron deficient anemia.

The current weakness in shares of BioSysent (TSXV:RX) is a buying opportunity, says Cantor Fitzgerald Canada analyst Scott Curtis. In a research update to clients yesterday, Curtis reiterated his “Speculative Buy” rating and $13.25 one-year target on BioSyent, implying a return of 58% at the time of publication. Curtis says despite recent nervousness in the […]

Is radioactivity from Fukushima dangerous to British Columbians?

Woods Hole Oceanographic Institution  marine radiochemist Ken Buesseler in front of the Fukushima Dai-ichi nuclear plant. (Photo courtesy Ken Buesseler)

After calling on the public to help gather samples, scientists at the Massachusetts-based Woods Hole Oceanographic Institution says traces of radioactivity from the meltdown 2011 meltdown of Japan’s Fukushima Daiichi nuclear plan are showing up in B.C. waters. But researchers says there is good news: the levels of radioactivity likely pose no threat. “Radioactivity can […]

Medicure is Persevering on the Prairies


I am a proud Manitoban, and not only do I cheer for the Jets, I cheer for all things Manitoba. I cut my life science teeth so-to-speak, as a drug rep covering Manitoba, Saskatchewan and Northwest Ontario – God’s Country. While completing an MBA at the Asper School of Business, I was recruited away from […]

Theratechnologies Is Reinventing Itself


It would be an understatement to say that specialty pharma companies have been popular among Canadian investors of late. A quick scan of the one-year charts on Cipher Pharmaceuticals (TSX:CPH), Concordia Healthcare (TSX:CXR), and BioSyent (TSXV:RX) is illustrative of how in vogue this sector has become. With the space squarely on Canadian investor’s radar, I […]

Ottawa’s Privacy Analytics Participates in HITRUST Health De-Identification Framework


A U.S. coalition called HITRUST has created a De-Identification Framework for the healthcare industry, setting standards and controls for improving cybersecurity relating to patient health records. A Canadian company that specializes in data anonymization for the health industry, Ottawa’s Privacy Analytics, played a role in the framework’s development. De-Identification, in a nutshell, provides a way […]

Concordia Healthcare acquisition of Covis gets thumbs up at Laurentian

concordia healthcare

Laurentian Bank Securities analyst Joseph Walewicz likes Concordia Health Care’s (TSX:CXR) acquisition of Covis Pharma. This morning, Concordia announced it would buy Covis Pharma SARL and Covis Injectables SARL for (U.S.) $1.2-billion in cash. The company said it would finance the pickup through a combination of term loans, bonds and equity. “Covis’s strong commercial momentum […]